OPTIMAL VERSUS MAXIMALLY TOLERATED DOSE IN CANCER-CHEMOTHERAPY TREATMENT

被引：3

作者：

MARKMAN, M ^{[1
]}

机构：

[1] CLEVELAND CLIN FDN,DEPT HEMATOL MED ONCOL,CLEVELAND,OH 44195

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 1993年 / 119卷 / 10期

关键词：

D O I：

10.1007/BF01372720

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：576 / 577

页数：2

共 15 条

[1] EFFECT OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ON HEMATOPOIETIC RECONSTITUTION AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].

BRANDT, SJ ;

PETERS, WP ;

ATWATER, SK ;

KURTZBERG, J ;

BOROWITZ, MJ ;

JONES, RB ;

SHPALL, EJ ;

BAST, RC ;

GILBERT, CJ ;

OETTE, DH .

NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (14) :869-876

[2] PHASE-II STUDY OF TAXOL, MERBARONE, AND PIROXANTRONE IN STAGE-IV NON-SMALL-CELL LUNG-CANCER - THE EASTERN COOPERATIVE ONCOLOGY GROUP RESULTS [J].

CHANG, AY ;

KIM, K ;

GLICK, J ;

ANDERSON, T ;

KARP, D ;

JOHNSON, D .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :388-394

[3] RAPID DELIVERY OF MULTIPLE HIGH-DOSE CHEMOTHERAPY COURSES WITH GRANULOCYTE COLONY-STIMULATING FACTOR AND PERIPHERAL BLOOD-DERIVED HEMATOPOIETIC PROGENITOR CELLS [J].

CROWN, J ;

WASSHERHEIT, C ;

HAKES, T ;

FENNELLY, D ;

REICH, L ;

MOORE, M ;

SCHNEIDER, J ;

CURTIN, J ;

RUBIN, SC ;

REICHMAN, B ;

MOORE, M ;

YAO, TJ ;

GILEWSKI, T ;

GULATI, S ;

MARKMAN, M ;

NORTON, L .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (24) :1935-1936

[4] PHASE-II STUDY AND LONG-TERM FOLLOW-UP OF PATIENTS TREATED WITH TAXOL FOR ADVANCED OVARIAN ADENOCARCINOMA [J].

EINZIG, AI ;

WIERNIK, PH ;

SASLOFF, J ;

RUNOWICZ, CD ;

GOLDBERG, GL .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1748-1753

[5] EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR ON NEUTROPENIA AND ASSOCIATED MORBIDITY DUE TO CHEMOTHERAPY FOR TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIUM [J].

GABRILOVE, JL ;

JAKUBOWSKI, A ;

SCHER, H ;

STERNBERG, C ;

WONG, G ;

GROUS, J ;

YAGODA, A ;

FAIN, K ;

MOORE, MAS ;

CLARKSON, B ;

OETTGEN, HF ;

ALTON, K ;

WELTE, K ;

SOUZA, L .

NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (22) :1414-1422

[6] PHASE-II TRIAL OF TAXOL, AN ACTIVE-DRUG IN THE TREATMENT OF METASTATIC BREAST-CANCER [J].

HOLMES, FA ;

WALTERS, RS ;

THERIAULT, RL ;

FORMAN, AD ;

NEWTON, LK ;

RABER, MN ;

BUZDAR, AU ;

FRYE, DK ;

HORTOBAGYI, GN .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (24) :1797-1805

[7]

LEGHA SS, 1990, CANCER, V65, P2478, DOI 10.1002/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO

[8]

2-S

[9] TAXOL - A UNIQUE ANTINEOPLASTIC AGENT WITH SIGNIFICANT ACTIVITY IN ADVANCED OVARIAN EPITHELIAL NEOPLASMS [J].

MCGUIRE, WP ;

ROWINSKY, EK ;

ROSENSHEIN, NB ;

GRUMBINE, FC ;

ETTINGER, DS ;

ARMSTRONG, DK ;

DONEHOWER, RC .

ANNALS OF INTERNAL MEDICINE, 1989, 111 (04) :273-279

[10]

MORSTYN G, 1988, CANCER RES, V48, P5624

← 1 2 →